These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1799 related items for PubMed ID: 25211326

  • 1. Interference with the expression of β-catenin reverses cisplatin resistance in A2780/DDP cells and inhibits the progression of ovarian cancer in mouse model.
    Zhao H, Wei W, Sun Y, Gao J, Wang Q, Zheng J.
    DNA Cell Biol; 2015 Jan; 34(1):55-62. PubMed ID: 25211326
    [Abstract] [Full Text] [Related]

  • 2. Oridonin effectively reverses cisplatin drug resistance in human ovarian cancer cells via induction of cell apoptosis and inhibition of matrix metalloproteinase expression.
    Ma S, Tan W, Du B, Liu W, Li W, Che D, Zhang G.
    Mol Med Rep; 2016 Apr; 13(4):3342-8. PubMed ID: 26935490
    [Abstract] [Full Text] [Related]

  • 3. Inhibition of cytoplasmic GSK-3β increases cisplatin resistance through activation of Wnt/β-catenin signaling in A549/DDP cells.
    Gao Y, Liu Z, Zhang X, He J, Pan Y, Hao F, Xie L, Li Q, Qiu X, Wang E.
    Cancer Lett; 2013 Aug 09; 336(1):231-9. PubMed ID: 23673211
    [Abstract] [Full Text] [Related]

  • 4. Lentivirus-Mediated RNAi silencing targeting ERCC1 reverses cisplatin resistance in cisplatin-resistant ovarian carcinoma cell line.
    Du P, Zhang X, Liu H, Chen L.
    DNA Cell Biol; 2015 Jul 09; 34(7):497-502. PubMed ID: 25941922
    [Abstract] [Full Text] [Related]

  • 5. Effect of lung resistance-related protein on the resistance to cisplatin in human ovarian cancer cell lines.
    Wang W, Ke S, Chen G, Gao Q, Wu S, Wang S, Zhou J, Yang X, Lu Y, Ma D.
    Oncol Rep; 2004 Dec 09; 12(6):1365-70. PubMed ID: 15547764
    [Abstract] [Full Text] [Related]

  • 6. Downregulation of gene MDR1 by shRNA to reverse multidrug-resistance of ovarian cancer A2780 cells.
    Zhang H, Wang J, Cai K, Jiang L, Zhou D, Yang C, Chen J, Chen D, Dou J.
    J Cancer Res Ther; 2012 Dec 09; 8(2):226-31. PubMed ID: 22842366
    [Abstract] [Full Text] [Related]

  • 7. [Role of apoptosis-associated genes and caspase-3 in cisplatin-resistant human ovarian cancer cell lines].
    Yang XK, Xing H, Zheng F, Gao QL, Wang W, Lu YP, Ma D.
    Zhonghua Fu Chan Ke Za Zhi; 2003 Mar 09; 38(3):158-61. PubMed ID: 12816691
    [Abstract] [Full Text] [Related]

  • 8. XIAP gene downregulation by small interfering RNA inhibits proliferation, induces apoptosis, and reverses the cisplatin resistance of ovarian carcinoma.
    Ma JJ, Chen BL, Xin XY.
    Eur J Obstet Gynecol Reprod Biol; 2009 Oct 09; 146(2):222-6. PubMed ID: 19758744
    [Abstract] [Full Text] [Related]

  • 9. Recovery of miR-139-5p in Ovarian Cancer Reverses Cisplatin Resistance by Targeting C-Jun.
    Jiang Y, Jiang J, Jia H, Qiao Z, Zhang J.
    Cell Physiol Biochem; 2018 Oct 09; 51(1):129-141. PubMed ID: 30439707
    [Abstract] [Full Text] [Related]

  • 10. Knockdown of MACC1 expression increases cisplatin sensitivity in cisplatin-resistant epithelial ovarian cancer cells.
    Zhang R, Shi H, Ren F, Li X, Zhang M, Feng W, Jia Y.
    Oncol Rep; 2016 Apr 09; 35(4):2466-72. PubMed ID: 26794135
    [Abstract] [Full Text] [Related]

  • 11. C-Myc participates in β-catenin-mediated drug resistance in A549/DDP lung adenocarcinoma cells.
    Xie C, Pan Y, Hao F, Gao Y, Liu Z, Zhang X, Xie L, Jiang G, Li Q, Wang E.
    APMIS; 2014 Dec 09; 122(12):1251-8. PubMed ID: 25131138
    [Abstract] [Full Text] [Related]

  • 12. HDAC1 Silencing in Ovarian Cancer Enhances the Chemotherapy Response.
    Liu X, Yu Y, Zhang J, Lu C, Wang L, Liu P, Song H.
    Cell Physiol Biochem; 2018 Dec 09; 48(4):1505-1518. PubMed ID: 30071534
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [Inhibition of Topo II alpha gene expression and reversing of drug resistance in multi-drug resistant epithelial ovarian cancer cells induced by RNA interference in vitro].
    He J, Li L, Tang BJ, Zhang W, Li DR, Wang Q.
    Zhonghua Fu Chan Ke Za Zhi; 2009 Sep 09; 44(9):686-90. PubMed ID: 20079182
    [Abstract] [Full Text] [Related]

  • 16. MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: a novel epigenetic therapy independent of decitabine.
    Xiang Y, Ma N, Wang D, Zhang Y, Zhou J, Wu G, Zhao R, Huang H, Wang X, Qiao Y, Li F, Han D, Wang L, Zhang G, Gao X.
    Oncogene; 2014 Jan 16; 33(3):378-86. PubMed ID: 23318422
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Regulation of HtrA2/Omi by X-linked inhibitor of apoptosis protein in chemoresistance in human ovarian cancer cells.
    Yang X, Xing H, Gao Q, Chen G, Lu Y, Wang S, Ma D.
    Gynecol Oncol; 2005 May 16; 97(2):413-21. PubMed ID: 15863139
    [Abstract] [Full Text] [Related]

  • 19. Inhibition of the IGF signaling pathway reverses cisplatin resistance in ovarian cancer cells.
    Du J, Shi HR, Ren F, Wang JL, Wu QH, Li X, Zhang RT.
    BMC Cancer; 2017 Dec 14; 17(1):851. PubMed ID: 29241458
    [Abstract] [Full Text] [Related]

  • 20. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
    Horowitz NS, Hua J, Gibb RK, Mutch DG, Herzog TJ.
    Gynecol Oncol; 2004 Jul 14; 94(1):67-73. PubMed ID: 15262121
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 90.